CASC
AQST icon

Coppell Advisory Solutions Corp’s Aquestive Therapeutics AQST Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37
Closed -$33 – 251
2022
Q4 		$33 Buy
+37
New +$35 ﹤0.01% 1180

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Coppell Advisory Solutions Corp's AQST Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Aquestive Therapeutics (AQST) in Q1 2023, closing a stake of 37 shares — an estimated $33 sold.

Coppell Advisory Solutions Corp first reported a position in AQST in Q4 2022 and held it in 1 quarter. The position peaked at $33 in Q4 2022. 35 funds tracked by Wall St. Rank hold AQST as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Aquestive Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 37 Aquestive Therapeutics shares in Q1 2023, an estimated $33.
  • Coppell Advisory Solutions Corp first reported a position in Aquestive Therapeutics in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Aquestive Therapeutics position peaked at $33 in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.